<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03150810</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-103</org_study_id>
    <nct_id>NCT03150810</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Myriad Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, efficacy and clinical activity of BGB-290 and
      temozolomide (TMZ) in subjects with locally advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study of BGB‑290 and temozolomide (TMZ) with a dose escalation and dose
      expansion phase. Dose escalation will evaluate safety, tolerability, preliminary efficacy,
      and PK and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) for
      the two drug combination. It is a modified 3+3 dose escalation scheme with a fixed dose of
      BGB‑290 in combination with escalating doses of TMZ. Dose expansion will evaluate the safety,
      PK profile and anti-tumor activity of BGB-290 and TMZ at a dose/schedule selected from the
      dose escalation phase. Five different solid malignancy types (n=100) will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) as assessed by CTCAE.</measure>
    <time_frame>From first dose BGB-290 to 28 days post-dosing.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, nature and severity of adverse events as assessed by CTCAE.</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dosing.]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters (Cmax) of BGB-290 and TMZ.</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) parameters (Tmax) of BGB-290 and TMZ.</measure>
    <time_frame>From first dose BGB-290 to 30 days post-dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as assessed using RECIST.</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 5 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR).</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression while subject is alive, assessed to up 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From first dose BGB-290 to first documentation of disease progression or death, whichever is first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From first dose BGB-290 until date of death, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Locally Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 subjects to receive continuous BGB-290 and TMZ (Days 1 - 7 of 28 day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 25 subjects to receive continuous BGB-290 and continuous TMZ (28-day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Dose Expansion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 100 subjects to receive BGB-290 and TMZ.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-290</intervention_name>
    <description>BGB-290</description>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>TMZ</description>
    <arm_group_label>Arm A (Dose Escalation)</arm_group_label>
    <arm_group_label>Arm B (Dose Escalation)</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-290</intervention_name>
    <description>Dose/schedule selected based on dose escalation phase.</description>
    <arm_group_label>Arm C (Dose Expansion)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>Dose/schedule selected based on dose escalation phase.</description>
    <arm_group_label>Arm C (Dose Expansion)</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All subjects

          1. Age ≥18 years old.

          2. Confirmed malignancy at advanced or metastatic stage.

          3. ECOG status ≤ 1.

          4. Adequate bone marrow function.

          5. Adequate renal and hepatic function.

          6. Females of childbearing potential and non-sterile males must agree to use highly
             effective methods of birth control throughout the course of study and at least up to
             90 days after last dosing.

          7. Must have measurable or evaluable disease per RECIST [Dose escalation phase only]

             Additional inclusion criteria 8 - 12 are specific to tumor types in dose expansion
             phase:

          8. Ovarian cancer

               1. Previously received at least 1 line of platinum containing chemotherapy.

               2. No progression or recurrent disease in 6 months from last platinum containing
                  regimen.

          9. Triple-Negative Breast Cancer

             a. 0 - 1 prior platinum-containing regimen (any treatment setting) and received ≤ 3
             prior regimens (advanced or metastatic setting).

         10. Prostate cancer

               1. Documented progressive disease.

               2. Chemotherapy-naïve or previously received ≤2 taxane-based regimens.

               3. May be pre-or post-treatment with a novel androgen receptor targeted agent.

               4. Completed in ≥ 2 weeks radiation or treatment with anti-androgen agents.

         11. Ovarian, breast and prostate cancer: If homologous recombinant deficiency (HRD) or
             BRCA status unknown, need pre-screening for eligibility.

         12. Small cell lung and gastric cancer: previously received ≤ 2 prior lines of therapy.

        Exclusion Criteria: All subjects

          1. Prior exposure to a PARP inhibitor.

          2. Prior chemotherapy, biologic therapy, immunotherapy or investigational agents within 3
             weeks prior to start of study treatment.

          3. Refractory to platinum-based therapy.

          4. Toxicity of ≥ Grade 2 from prior therapy.

          5. Major surgery or significant injury ≤ 4 weeks prior to start of study treatment.

          6. History of other active malignancies within 2 years with exception of (i) adequately
             treated in situ carcinoma of the cervix, (ii) non-melanoma skin cancer, or (iii)
             localized adequately treated cancer with curative intent or malignancy diagnosed &gt; 2
             years ago with no evidence of disease and no treatment ≤ 2 years prior to study
             treatment.

          7. Untreated leptomeningeal or brain metastasis.

          8. Active infection requiring systemic treatment.

          9. Known human immunodeficiency virus (HIV) or active viral hepatitis.

         10. Active, clinically significant cardiac disease or any Class 3 or 4 cardiac disease,
             ventricular arrhythmia or CVA ≤ 6 months prior to start of treatment.

         11. Active, clinically significant gastrointestinal disease.

         12. Use of any medications or food known to be strong or moderate cytochrome P450, family
             3, subfamily A (CYP3A) inhibitors or strong inducers.

         13. Pregnant or nursing females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katie Wood, PhD</last_name>
    <phone>831-218-5309</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rainer Brachmann, MD</last_name>
    <phone>831-512-1073</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Estkowski, BS, CCRP</last_name>
    </contact>
    <contact_backup>
      <last_name>Yvette C. Cole, RN, BSN, OCN</last_name>
    </contact_backup>
    <investigator>
      <last_name>Nehal Lakhani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Meredith, MD</last_name>
    </contact>
    <investigator>
      <last_name>Haesong Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai - PRIME</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Galsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center PRIME</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sanjay Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute (Tennessee Oncology)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Streck</last_name>
    </contact>
    <contact_backup>
      <last_name>Jessica Bondurant</last_name>
    </contact_backup>
    <investigator>
      <last_name>John Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2017</study_first_submitted>
  <study_first_submitted_qc>May 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Small cell lung cancer</keyword>
  <keyword>Prostate cancer,</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>neoplasms</keyword>
  <keyword>temozolomide</keyword>
  <keyword>BGB-290</keyword>
  <keyword>antineoplastic agents</keyword>
  <keyword>alkylating, alkylating agents,</keyword>
  <keyword>Poly (ADP-ribose) polymerase inhibitors</keyword>
  <keyword>enzyme inhibitors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

